87/100B167.530
USD
-0.07
(-0.04%)
Market Open
Last updated: · Delayed 15 min
If you had invested in Gilead Sciences ago, it would be worth $3,130 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
87/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Gilead Sciences key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Speculative (losing money)
- Day range
- 166.970 – 168.715
- 52-week range
- 116.880 – 176.580
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 207.79B USD
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- -3.10
- Div YieldWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 1.96%
- EPS growth forecast (FY2026)
- -110.7%
- Volume
- 32,462
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.37
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 54.1/100Environment 50 · Social 58 · Governance 55
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day
- Employees
- 17K
- Website
- gilead.com
- IPO date
- 22 Jan 1992
Gilead Sciences earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
1.29 USD
Revenue estimate
8.30B USD
Last quarter · Q3 FY2026
EPS2.55Beat +16.4%Revenue8.30BBeat +6.3%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 2.17 | — | — | +7.12% | 7.48B | — | — | +7.54% | |
| Q4 FY2026 | 1.29 | — | — | -30.65% | 8.30B | — | — | +4.71% | |
| Q3 FY2026 | 2.19 | 2.55 | +16.44% | +3.24% | 7.81B | 8.30B | +6.34% | +6.83% | |
| Q2 FY2026 | -7.25 | -6.75 | +6.90% | -435.82% | 7.40B | 7.80B | +5.47% | +10.20% | |
| Q1 FY2026 | 1.91 | 2.03 | +6.28% | +12.15% | 6.91B | 6.96B | +0.67% | +4.39% | |
| Q4 FY2025 | 1.81 | 1.86 | +2.76% | -2.11% | 7.69B | 7.93B | +3.05% | +4.70% | |
| Q3 FY2025 | 2.13 | 2.47 | +15.96% | +22.28% | 7.45B | 7.77B | +4.35% | +2.97% | |
| Q2 FY2025 | 1.96 | 2.01 | +2.55% | 0.00% | 6.98B | 7.08B | +1.43% | +1.90% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 10.76 | — | — | +6.34% | 34.71B | — | — | +3.51% |
| FY2027 | 10.12 | — | — | — | 33.53B | — | — | +7.05% |
| FY2026 | -0.87 | — | — | -110.68% | 31.32B | — | — | +6.39% |
| FY2025 | 8.11 | 8.15 | +0.46% | +76.79% | 29.23B | 29.44B | +0.73% | +2.41% |
| FY2024 | 4.41 | 4.61 | +4.54% | -31.40% | 28.32B | 28.75B | +1.51% | +6.02% |
| FY2023 | 6.75 | 6.72 | -0.51% | -7.57% | 27.10B | 27.12B | +0.06% | -0.60% |
| FY2022 | 7.10 | 7.27 | +2.35% | -0.27% | 26.53B | 27.28B | +2.84% | -0.09% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Gilead Sciences analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
167.14 USD
-0.23%
Analysts' 1-year price targets range from 126.00 to 196.00, with an average of 167.14.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
16 ratings
| Buy | 13 | |
| Hold | 3 | |
| Sell | 0 |
12-month price target
| Highest target | 196.00 |
| Average target | 167.14 |
| Lowest target | 126.00 |
| Current price | 167.53 |
Gilead Sciences valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Forward P/E (FY2027)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 16.55
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 6.71
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 15.94
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 276.53
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
207.79B USD
+
Total debt
26.23B USD
−
Cash and short-term investments
6.44B USD
=
Enterprise value
227.59B USD
Valuation over time
P/EForward P/EForward P/E · Estimate
Gilead Sciences against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Amgen, Pfizer, Bristol-Myers Squibb, Merck & Co., AbbVie, and Johnson & Johnson, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginAbove its median78.8%75.8%79.3%Against its peers: 1 of 7Peers' median 70.9%
- Operating marginAbove its median34.0%5.8%36.3%Against its peers: 2 of 7Peers' median 28.8%
- Net marginHighest in 5 years28.9%1.7%28.9%Against its peers: 1 of 7Peers' median 17.8%
- Return on equityHighest in 5 years37.5%2.5%37.5%Against its peers: 3 of 6Peers' median 34.7%
- Free cash flow marginAt its median32.1%27.4%39.6%Against its peers: 1 of 7Peers' median 21.5%
- Revenue growthAt its median2.4%-0.6%10.6%Against its peers: 4 of 7Peers' median 3.6%
- EPS growthAbove its median1,684.2%-91.6%4,961.6%Against its peers: 1 of 6Peers' median 8.0%
- Debt to EBITDALowest in 5 years1.84×1.84×6.02×Against its peers: 3 of 7Peers' median 3.16×
- Current ratioAbove its median1.551.271.60Against its peers: 1 of 7Peers' median 1.15
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Gilead Sciences growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 30.99B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- -3.86B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 79.93%
- Operating margin
- -7.62%
- Net margin
- -12.47%
Revenue / Net income
Revenue Net income Net margin
Gilead Sciences revenue breakdown
By product
FY2025
48.7%Biktarvy9.4%Descovy5.1%Genvoya5.1%Yescarta4.7%Trodelvy4.3%Sofosbuvir/Velpatasvir4.0%Odefsey3.6%Vemlidy3.1%Veklury3.0%Other Liver Disease1.8%Royalty, contract and other revenues1.7%AmBisome1.7%Other HIV1.7%Symtuza - Revenue share1.2%Tecartus
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Biktarvy | 14.33B | 48.7% | — |
| Descovy | 2.76B | 9.4% | — |
| Genvoya | 1.50B | 5.1% | — |
| Yescarta | 1.50B | 5.1% | — |
| Trodelvy | 1.40B | 4.7% | +6.2% |
| Sofosbuvir/Velpatasvir | 1.27B | 4.3% | — |
| Odefsey | 1.17B | 4.0% | — |
| Vemlidy | 1.07B | 3.6% | — |
| Veklury | 911.00M | 3.1% | -49.4% |
| Other Liver Disease | 874.00M | 3.0% | — |
| Royalty, contract and other revenues | 527.00M | 1.8% | — |
| AmBisome | 509.00M | 1.7% | — |
| Other HIV | 500.00M | 1.7% | -97.5% |
| Symtuza - Revenue share | 495.00M | 1.7% | — |
| Tecartus | 344.00M | 1.2% | — |
| Other | 290.00M | 1.0% | — |
By region
FY2025
70.9%United States17.2%Europe11.9%Other International
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| United States | 20.88B | 70.9% | +1.4% |
| Europe | 5.06B | 17.2% | +9.3% |
| Other International | 3.50B | 11.9% | -0.7% |
How Gilead Sciences makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Biktarvy14.33B 48.7%
Descovy2.76B 9.4%
Genvoya1.50B 5.1%
Yescarta1.50B 5.1%
Trodelvy1.40B 4.7%
Sofosbuvir/Velpatasvir1.27B 4.3%
Odefsey1.17B 4.0%
Vemlidy1.07B 3.6%
Veklury911.00M 3.1%
Other Liver Disease874.00M 3.0%
Royalty, contract and other revenues527.00M 1.8%
AmBisome509.00M 1.7%
Other HIV500.00M 1.7%
Symtuza - Revenue share495.00M 1.7%
Tecartus344.00M 1.2%
Other290.00M 1.0%
Revenue29.44B 100.0%
Cost of revenue6.23B 21.2%
Gross profit23.21B 78.8%
Research and development5.80B 19.7%
Selling and administration5.71B 19.4%
Other operating expenses1.68B 5.7%
Operating income10.02B 34.0%
Tax1.29B 4.4%
Other expense226.00M 0.8%
Net income8.51B 28.9%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Gilead Sciences dividendsWhat is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- Annual dividend
- 3.28 USD
- Dividend yield (indicated)What is dividend yield? Dividend yield is a year of dividends as a percentage of the share price: the income a shareholder receives for each dollar invested at today's price.
- 1.96%
- Years of dividend growthWhat are years of dividend growth? The years in a row a company has raised its dividend per share. 25 years make an S&P 500 company a Dividend Aristocrat; 50 make a Dividend King.
- 11
- Frequency
- Quarterly
- Next payment
- 0.82 USD
- Next ex-dividend dateWhat is the ex-dividend date? The ex-dividend date is the first day a stock trades without its next dividend: buy before it to receive the payment; buy on or after it and the seller gets it.
- 15 Dec 2026
- Next payment date
- 30 Dec 2026
Dividends per share
Gilead Sciences financial health
- Cash and short-term investments
- 6.44B USD
- Total debt
- 26.23B USD
- Net cash
- -19.79B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 13.78B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.38
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 2.01
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 5 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.90
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Gilead Sciences ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 90.19%
- Institutional holders
- 2,377 (-37)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.79%
Who owns the shares
Institutions 90.2% Others 9.8%
As of 30 Jun 2026
Shares free to trade
Free float 1.24B shares ·99.8% Closely held 2.63M shares ·0.2%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 12 | 128.31K | 292.62K |
| Q3 2026 | 0 | 26 | 71.72K | 193.87K |
| Q2 2026 | 0 | 16 | 88.73K | 116.16K |
| Q1 2026 | 0 | 17 | 923.23K | 772.18K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling PrepVerified against SEC filings
Title: Gilead Sciences
Sector: Healthcare
Industry: Drug Manufacturers - General
Gilead Sciences Inc. is an American biopharmaceutical firm that was founded in 1987 under the name Oligogen by Michael L. Riordan. The company specializes in the research, development and sale of medicines in underdeveloped research areas. To this end, the company engages its research in such areas as the human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under many brand names, including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Sovaldi and more. The company is headquartered in Foster, California, and its stock is measured on the NASDAQ Biotechnology Index and the S&P 500 Index.